7.03 USD
+0.03 (+0.43%)
Taking everything into account, MDXG scores 6 out of 10 in our fundamental rating. MDXG was compared to 530 industry peers in the Biotechnology industry. While MDXG has a great health rating, its profitability is only average at the moment. MDXG scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make MDXG suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year MDXG was profitable.
MDXG had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MDXG reported negative net income in multiple years.
In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
MDXG's Return On Assets of 12.80% is amongst the best of the industry. MDXG outperforms 94.34% of its industry peers.
MDXG's Return On Equity of 17.09% is amongst the best of the industry. MDXG outperforms 95.09% of its industry peers.
MDXG has a Return On Invested Capital of 15.15%. This is amongst the best in the industry. MDXG outperforms 95.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 10.38%, MDXG belongs to the best of the industry, outperforming 91.32% of the companies in the same industry.
MDXG has a better Operating Margin (13.73%) than 92.83% of its industry peers.
In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
Looking at the Gross Margin, with a value of 81.99%, MDXG belongs to the top of the industry, outperforming 85.66% of the companies in the same industry.
In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
MDXG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for MDXG has been increased compared to 1 year ago.
Compared to 5 years ago, MDXG has more shares outstanding
Compared to 1 year ago, MDXG has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 10.05 indicates that MDXG is not in any danger for bankruptcy at the moment.
MDXG's Altman-Z score of 10.05 is amongst the best of the industry. MDXG outperforms 82.08% of its industry peers.
The Debt to FCF ratio of MDXG is 0.27, which is an excellent value as it means it would take MDXG, only 0.27 years of fcf income to pay off all of its debts.
MDXG has a better Debt to FCF ratio (0.27) than 95.28% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that MDXG is not too dependend on debt financing.
MDXG has a worse Debt to Equity ratio (0.07) than 62.64% of its industry peers.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 10.05 |
ROIC/WACC1.74
WACC8.72%
2.3 Liquidity
A Current Ratio of 4.41 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Current ratio of 4.41. This is comparable to the rest of the industry: MDXG outperforms 50.94% of its industry peers.
A Quick Ratio of 3.95 indicates that MDXG has no problem at all paying its short term obligations.
MDXG's Quick ratio of 3.95 is in line compared to the rest of the industry. MDXG outperforms 48.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
MDXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.71%.
MDXG shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.77%.
MDXG shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.11% yearly.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
3.2 Future
The Earnings Per Share is expected to grow by 16.54% on average over the next years. This is quite good.
The Revenue is expected to grow by 14.49% on average over the next years. This is quite good.
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue Next Year18%
Revenue Next 2Y9.77%
Revenue Next 3Y10.75%
Revenue Next 5Y14.49%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 19.53, which indicates a rather expensive current valuation of MDXG.
MDXG's Price/Earnings ratio is rather cheap when compared to the industry. MDXG is cheaper than 94.72% of the companies in the same industry.
When comparing the Price/Earnings ratio of MDXG to the average of the S&P500 Index (26.50), we can say MDXG is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 28.13, the valuation of MDXG can be described as expensive.
MDXG's Price/Forward Earnings ratio is rather cheap when compared to the industry. MDXG is cheaper than 92.45% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.93, MDXG is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.53 | ||
| Fwd PE | 28.13 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaper than 95.47% of the companies in the same industry.
MDXG's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MDXG is cheaper than 96.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.58 | ||
| EV/EBITDA | 13.3 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MDXG has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MDXG's earnings are expected to grow with 16.54% in the coming years.
PEG (NY)0.41
PEG (5Y)N/A
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
5. Dividend
5.1 Amount
No dividends for MDXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:MDXG (12/24/2025, 11:34:26 AM)
7.03
+0.03 (+0.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.78%
Inst Owner Change-0.7%
Ins Owners1.79%
Ins Owner Change-0.16%
Market Cap1.04B
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target12.44 (76.96%)
Short Float %3.06%
Short Ratio4.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.15%
EPS NY rev (1m)-1.18%
EPS NY rev (3m)29.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)5.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.53 | ||
| Fwd PE | 28.13 | ||
| P/S | 2.65 | ||
| P/FCF | 15.58 | ||
| P/OCF | 15.35 | ||
| P/B | 4.36 | ||
| P/tB | 5 | ||
| EV/EBITDA | 13.3 |
EPS(TTM)0.36
EY5.12%
EPS(NY)0.25
Fwd EY3.55%
FCF(TTM)0.45
FCFY6.42%
OCF(TTM)0.46
OCFY6.51%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.41
PEG (5Y)N/A
Graham Number3.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 10.05 |
F-Score6
WACC8.72%
ROIC/WACC1.74
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year18%
Revenue Next 2Y9.77%
Revenue Next 3Y10.75%
Revenue Next 5Y14.49%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year63.46%
EBIT Next 3Y22.08%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
What is the valuation status of MIMEDX GROUP INC (MDXG) stock?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
What is the profitability of MDXG stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
What is the valuation of MIMEDX GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 19.53 and the Price/Book (PB) ratio is 4.36.
What is the financial health of MIMEDX GROUP INC (MDXG) stock?
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.